This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sarissa Capital Urges All Shareholders Of Astex Pharmaceuticals To Not Tender Their Shares At Current $8.50 Price

GREENWICH, Conn., Oct. 8, 2013 /PRNewswire/ -- Sarissa Capital today issued the following open letter to shareholders of Astex Pharmaceuticals, Inc. (NASDAQ: ASTX):

Dear Fellow Shareholders,

We are one of Astex's largest shareholders, owning approximately 5% of the outstanding shares of the company.  On October 2, 2013, we issued an open letter which expressed our view that the recently announced merger transaction with Otsuka Pharmaceutical significantly undervalued Astex, and that, accordingly, we did not intend to tender our shares at this price.  We urge you NOT to tender your shares at this price.

Shortly after we released our letter, Astex issued an open letter, apparently to respond to our and other shareholders' concerns about the current transaction.  We do not believe Astex addressed any of our concerns in a substantive way.  Instead, their letter seemed to us to be primarily an attempt to scare Astex shareholders into tendering into the offer by suggesting that a decision to not tender would "impose substantial additional risk that Otsuka could ultimately walk away from the transaction."  Given the built-in mandatory offer extensions in the Astex-Otsuka transaction agreement that we outlined in our October 2 letter, we don't believe any such "substantial additional risk" exists.  But most importantly, we do not believe that $8.50 is an adequate price.

Therefore, we do NOT intend to tender our shares and we urge all Astex shareholders NOT to tender their shares at this price.


/s/ Alexander J. Denner, Ph.D./s/ Richard C. Mulligan, Ph.D./s/ Mayu Sris

Sarissa Capital Management LP

SOURCE Sarissa Capital Management LP
Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.04 -0.21%
FB $117.72 -0.08%
GOOG $703.46 0.29%
TSLA $213.35 0.86%
YHOO $36.94 0.01%


Chart of I:DJI
DOW 17,667.39 +6.68 0.04%
S&P 500 2,049.06 -1.57 -0.08%
NASDAQ 4,707.9250 -9.1690 -0.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs